Escalating BMI Associated With the Complex Pharmacology of Propranolol: A Case Report

Abstract

Background: Improving the awareness of the public about the body weight and the body mass index (BMI) criteria is very important as increased body weight may be associated with an increased risk for many dangerous diseases and health complications. Propranolol is generally prescribed for tachycardia while its most common side effects are bradycardia and masking hypoglycemia. Case Presentation: A tachycardia was diagnosed in a young overweight woman and treated successfully with propranolol but this treatment, unpredictably, was associated with a rapid increase in the weight that classified her as obese. Discussion: The physical (body weight and heart rate) and the biochemical (blood glucose level) monitoring and analysis including the lifestyle provided a deeper insight into the principal details and helped to design a personalized treatment protocol.   Conclusion: A therapeutic dose of propranolol could be linked to uncommon mounting weight change which was associated with a decrease in the blood glucose level and an appetite enhancement.